PMID- 11073864
OWN - NLM
STAT- MEDLINE
DCOM- 20001207
LR  - 20190831
IS  - 1524-4636 (Electronic)
IS  - 1079-5642 (Linking)
VI  - 20
IP  - 11
DP  - 2000 Nov
TI  - Coimmobilized native macromolecular heparin proteoglycans strongly inhibit 
      platelet-collagen interactions in flowing blood.
PG  - E113-9
AB  - We coimmobilized mast cell-derived heparin proteoglycans (HEP-PGs) of very high 
      molecular weight (750 kDa) or unfractionated heparin (UFH) on coverslips together 
      with collagen without altering the amount of immobilized collagen. Subsequently, 
      platelet-collagen interactions were studied under both flowing and static 
      conditions in D-phenylalanyl-L-prolyl-L-arginine chloromethyl 
      ketone-anticoagulated blood and platelet-rich plasma (PRP), respectively. At a 
      high shear rate (1600 1/s), the mean platelet deposition (PD) on collagen 
      monomers was 7.5+/-6.1x10(6)/cm(2) (n=5). When the monomers were coimmobilized 
      with UFH, PD was inhibited by 73% (2.0+/-1.2x10(6)/cm(2)), whereas HEP-PG 
      completely blocked it (0. 42+/-0.38x10(6)/cm(2); P<0.05). Also, when collagen 
      fibrils were used for coating, HEP-PG significantly inhibited PD. At a low shear 
      rate (200 1/s) and under static conditions in PRP, the inhibitory effect of 
      HEP-PG on PD was less marked. Inhibition of glycoprotein IIb/IIIa did not affect 
      PD on coimmobilized HEP-PG in contrast to coimmobilized UFH or collagen alone. As 
      a sign of inactivation, platelets adhering to the HEP-PG surface released 
      considerably less beta-thromboglobulin than did those adhering to pure collagen. 
      In summary, immobilized HEP-PG strongly inhibited PD on collagen by attenuating 
      adhesion-induced platelet activation. The stronger effect on collagen monomers 
      suggests the inhibition of glycoprotein Ia/IIa-mediated activation.
FAU - Kauhanen, P
AU  - Kauhanen P
AD  - Wihuri Research Institute, Helsinki, Finland.
FAU - Kovanen, P T
AU  - Kovanen PT
FAU - Lassila, R
AU  - Lassila R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arterioscler Thromb Vasc Biol
JT  - Arteriosclerosis, thrombosis, and vascular biology
JID - 9505803
RN  - 0 (Glycosaminoglycans)
RN  - 0 (Heparan Sulfate Proteoglycans)
RN  - 0 (Macromolecular Substances)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (beta-Thromboglobulin)
RN  - 0 (von Willebrand Factor)
RN  - 9005-49-6 (Heparin)
RN  - 9007-34-5 (Collagen)
SB  - IM
MH  - Animals
MH  - Blood Flow Velocity
MH  - Blood Platelets/chemistry/*metabolism
MH  - Collagen/*antagonists & inhibitors/*blood
MH  - Glycosaminoglycans/blood
MH  - Heparan Sulfate Proteoglycans/*blood/isolation & purification/*physiology
MH  - Heparin/blood/pharmacology
MH  - Humans
MH  - Macromolecular Substances
MH  - Mast Cells/chemistry
MH  - Perfusion
MH  - Platelet Aggregation Inhibitors/blood/*pharmacology
MH  - Rats
MH  - beta-Thromboglobulin/metabolism
MH  - von Willebrand Factor/metabolism
EDAT- 2000/11/14 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/11/14 11:00
PHST- 2000/11/14 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/11/14 11:00 [entrez]
AID - 10.1161/01.atv.20.11.e113 [doi]
PST - ppublish
SO  - Arterioscler Thromb Vasc Biol. 2000 Nov;20(11):E113-9. doi: 
      10.1161/01.atv.20.11.e113.